Beyond breast cancer, in lung cancer cells, GPR81 activation reduces intracellular cyclic adenosine monophosphate (cAMP) levels and inhibits protein kinase A (PKA) activity, leading to the activation of the transcriptional coactivator TAZ. Here, HCAR1 is linked to lung carcinoma.